Top

Published in:

01-06-2021 | Dyslipidemia | Original Contributions

Comparative Effectiveness of Roux-en-Y Gastric Bypass vs. One Anastomosis Gastric Bypass on Kidney Function

Authors: Mohsen Mahmoudieh, Behrouz Keleidari, Pedram Hadipour, Erfan Sheikhbahaei, Alex R. Chang, Sina Ramtin, Shahab Shahabi

Published in: Obesity Surgery | Issue 6/2021

Abstract

Purpose

Obesity and its associated medical problems increase risk of kidney function decline while prior studies suggest that bariatric surgery may improve kidney outcomes. However, little is known about the comparative effectiveness of different types of bariatric surgery on kidney function. In this study, we compare the effects of laparoscopic one anastomosis gastric bypass (LOAGB) and laparoscopic Roux-en-Y gastric bypass (LRYGB) on kidney function one year after surgery.

Materials and Methods

The patients’ demographic, medical, and surgical data were prospectively collected and retrospectively reviewed. Type 2 diabetes mellitus, hypertension, and dyslipidemia, body mass index (BMI), and kidney function tests were obtained before and one year after surgery. Kidney function was evaluated by estimated glomerular filtration rate (eGFR) and spot urine albumin to creatinine ratio (ACR). Changes in eGFR and ACR were compared between LRYGB vs. LOAGB after adjustment for confounders (age, sex, remission of associated medical problems, preoperative BMI, and percentage of excess BMI loss) using ANCOVA model.

Results

Both surgical techniques significantly decreased the post-surgery presence of diabetes, hypertension, and dyslipidemia (p < 0.001 for all paired comparisons). The eGFR level significantly increased and the ACR level significantly decreased in both groups (p < 0.001 for all paired comparisons before and after adjustment). However, eGFR and ACR mean differences between LRYGB and LOAGB were not significantly different after adjustment for confounding variables (p = 0.9 and 0.4, respectively).

Conclusion

Both LOAGB and LRYGB improved 1-year eGFR and ACR equally independently from weight loss and other confounders.

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. Elsevier Inc.; 2019;92:6–10. Available from: https://doi.org/10.1016/j.metabol.2018.09.005.

Sayadi Shahraki M, Khalili N, Yousefvand S, Sheikhbahaei E, Shahabi Shahmiri S. Severe obesity and vitamin D deficiency treatment options before bariatric surgery: a randomized clinical trial. Surg Obes Relat Dis. Elsevier Inc.; 2019;15:1604–11. Available from: https://doi.org/10.1016/j.soard.2019.05.033.

Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Heal. Elsevier; 2016;19:602–13. Available from: https://doi.org/10.1016/j.jval.2016.02.008.

Rahmani A, Sayehmiri K, Asadollahi K, et al. Investigation of the prevalence of obesity in Iran: a systematic review and meta-analysis study. Acta Med Iran. 2015;53:596–607.PubMed

Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.CrossRef

Holcomb CN, Goss LE, Almehmi A, et al. Bariatric surgery is associated with renal function improvement. Surg Endosc. Springer US. 2018;32:276–81.CrossRef

Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364

Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of bariatric surgery in obese patients with hypertension the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension). Circulation. 2018;137:1132–42.CrossRef

Schiavon CA, Bhatt DL, Ikeoka D, et al. Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial. Ann Intern Med. 2020;173:685–93.CrossRef

10.

Coupaye M, Flamant M, Sami O, Calabrese D, Msika S, Bogard C, et al. Determinants of evolution of glomerular filtration rate after bariatric surgery: a 1-year observational study. Obes Surg. 2017;27:126–33. Available from: https://doi.org/10.1007/s11695-016-2260-7.

11.

D’Agati VD, Chagnac A, De Vries APJ, Levi M, Porrini E, Herman-Edelstein M, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. Nature Publishing Group; 2016;12:453–71. Available from: https://doi.org/10.1038/nrneph.2016.75.

12.

Cohen RV, Pereira TV, Aboud CM, et al. Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial. BMJ Open. 2017;7:e013574.CrossRef

13.

Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet. 2019;393:1299–309.CrossRef

14.

Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155:1–11.CrossRef

15.

Imam TH, Fischer H, Jing B, Burchette R, Henry S, DeRose SF, et al. Estimated GFR before and after bariatric surgery in CKD. Am J Kidney Dis. Elsevier Inc; 2017;69:380–8. Available from: https://doi.org/10.1053/j.ajkd.2016.09.020.

16.

Park S, Kim YJ, Choi CY, et al. Bariatric surgery can reduce albuminuria in patients with severe obesity and normal kidney function by reducing systemic inflammation. Obes Surg. 2018;28:831–7.CrossRef

17.

Magalhães DSC, Pedro JMP, Souteiro PEB, et al. Analyzing the impact of bariatric surgery in kidney function: a 2-year observational study. Obes Surg. 2019;29:197–206.CrossRef

18.

Ngoh CLY, So JBY, Tiong HY, Shabbir A, Teo BW. Effect of weight loss after bariatric surgery on kidney function in a multiethnic Asian population. Surg Obes Relat Dis. Elsevier; 2016;12:600–5. Available from: https://doi.org/10.1016/j.soard.2015.07.003.

19.

Hou CC, Shyu RS, Lee WJ, Ser KH, Lee YC, Chen SC. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis. Elsevier Inc.; 2013;9:202–6. Available from: https://doi.org/10.1016/j.soard.2012.10.005.

20.

Carbajo MA, Luque-de-León E, Jiménez JM, et al. Laparoscopic one-anastomosis gastric bypass: technique, results, and long-term follow-up in 1200 patients. Obes Surg. 2017;27:1153–67.CrossRef

21.

Lee WJ, Ser KH, Lee YC, et al. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg. 2012;22:1827–34.CrossRef

22.

Spivak H, Munz Y, Rubin M, Raz I, Shohat T, Blumenfeld O. Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis. Surg Obes Relat Dis. Elsevier Inc.; 2018;14:175–80. Available from: https://doi.org/10.1016/j.soard.2017.11.006.

23.

Garcia MS, Calderoni DR, Jimenez LS, et al. Renal function 1 year after bariatric surgery: influence of Roux-en-Y gastric bypass and identification of pre-operative predictors of improvement. Obes Surg. 2020;30:860–6.CrossRef

24.

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.CrossRef

25.

Kim EY, Kim YJ. Does bariatric surgery really prevent deterioration of renal function? Surg Obes Relat Dis. Elsevier; 2016;12:856–61. Available from: https://doi.org/10.1016/j.soard.2015.10.068.

26.

Magouliotis DE, Tasiopoulou VS, Tzovaras G. One anastomosis gastric bypass versus Roux-en-Y gastric bypass for morbid obesity: an updated meta-analysis. Obes Surg. 2019;29:2721–30.CrossRef

27.

Magouliotis DE, Tasiopoulou VS, Tzovaras G. One anastomosis gastric bypass versus Roux-en-Y gastric bypass for morbid obesity: a meta-analysis. Clin Obes. 2018;8:159–69.CrossRef

28.

Keleidari B, Mahmoudieh M, Shahabi S, Sheikhbahaei E, Rezaei M, Sayadi M, et al. Reversing one-anastomosis gastric bypass surgery due to severe and refractory hypoalbuminemia. World J Surg. Springer International Publishing; 2020;44:1200–8. Available from: https://doi.org/10.1007/s00268-019-05290-7.

29.

Keleidari B, Mahmoudieh M, Gorgi K, et al. Hepatic failure after bariatric surgery: a systematic review. Hepat Mon. 2019;19:1–16.

30.

Ruiz-Tovar J, Carbajo MA, Jimenez JM, Castro MJ, Gonzalez G, Ortiz-de-Solorzano J, et al. Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities. Surg Endosc. Springer US; 2019;33:401–10. Available from: https://doi.org/10.1007/s00464-018-6307-9.

31.

Docherty NG, le Roux C. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol. Springer US; 2020;16:709–20. Available from: https://doi.org/10.1038/s41581-020-0323-4.

32.

Choudhury RA, Hoeltzel G, Prins K, et al. Sleeve gastrectomy compared with gastric bypass for morbidly obese patients with end stage renal disease: a decision analysis. J Gastrointest Surg. 2020;24:756–63.CrossRef

33.

Bassiony AI, Sabry A, Shiha O, et al. The short-term renal effects of bariatric surgery: a comparative study between sleeve gastrectomy and one anastomosis gastric bypass operations among Egyptian patients with severe obesity. Obes Surg. 2020;30:4494–504.CrossRef

34.

De Luca M, Tie T, Ooi G, et al. Mini gastric bypass-one anastomosis gastric bypass (MGB-OAGB)—IFSO position statement. Obes Surg. 2018;28:1188–206.CrossRef

35.

De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, et al. Indications for surgery for obesity and weight-related diseases: position statements from the International Federation for the Surgery of Obesity and metabolic disorders (IFSO). Obes Surg. Obesity Surgery; 2016;26:1659–96. Available from: https://doi.org/10.1007/s11695-016-2271-4.

36.

Keleidari B, Mahmoudieh M, Kafi S, Shahabi S, Sheikhbahaei E, Farahmand A, et al. Which one is better for non-alcoholic fatty liver disease, the Roux-en-Y gastric bypass or one anastomosis gastric bypass? A paired liver biopsy report. Obes Med. Elsevier Ltd; 2020;18:100205. Available from: https://doi.org/10.1016/j.obmed.2020.100205.

37.

Mahmoudieh M, Keleidari B, Afshin N, et al. The early results of the laparoscopic mini-gastric bypass/one anastomosis gastric bypass on patients with different body mass index. J Obes. 2020;2020:1–6.CrossRef

38.

Mahmoudieh M, Keleidari B, Salimi M, Sayadi M, Shahabi S, Sheikhbahaei E. The two different biliopancreatic limb lengths for Roux-en-Y gastric bypass. Obes Med. Elsevier; 2019;16:100146. Available from: https://doi.org/10.1016/j.obmed.2019.100146.

39.

American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015;38:S8-16.

40.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRef

41.

Sadeghi M, Golshahi J, Talaei M, Sheikhbahaei E, Ghodjani E, Mansouri M, et al. 15-Year lipid profile effects on cardiovascular events adjusted for cardiovascular risk factors: a cohort study from Middle-East. Acta Cardiol. Taylor & Francis; 2020;0:1–6. Available from: https://doi.org/10.1080/00015385.2020.1717096.

42.

Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5:1003–9.CrossRef

43.

Saliba J, Kasim NR, Tamboli RA, Isbell JM, Marks P, Feurer ID, et al. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery. Mosby, Inc.; 2010;147:282–7. Available from: https://doi.org/10.1016/j.surg.2009.09.017.

44.

Neff KJ, Baud G, Raverdy V, Caiazzo R, Verkindt H, Noel C, et al. Renal function and Remission of hypertension after bariatric surgery: a 5-year prospective cohort study. Obes Surg. Obesity Surgery; 2017;27:613–9. Available from: https://doi.org/10.1007/s11695-016-2333-7.

45.

Friedman AN, Cohen RV. Bariatric surgery as a renoprotective intervention. Curr Opin Nephrol Hypertens. 2019;28:537–44.CrossRef

46.

Luaces M, Martínez-Martínez E, Medina M, et al. The impact of bariatric surgery on renal and cardiac functions in morbidly obese patients. Nephrol Dial Transplant. 2012;27:iv53–7.CrossRef

47.

Fenske WK, Dubb S, Bueter M, Seyfried F, Patel K, Tam FWK, et al. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. American Society for Metabolic and Bariatric Surgery; 2013;9:559–68. Available from: https://doi.org/10.1016/j.soard.2012.03.009.

48.

Bilha SC, Nistor I, Nedelcu A, et al. The effects of bariatric surgery on renal outcomes: a systematic review and meta-analysis. Obes Surg. 2018;28:3815–33.CrossRef

49.

Navaneethan SD, Malin SK, Arrigain S, et al. Bariatric surgery, kidney function, insulin resistance, and adipokines in patients with decreased GFR: A cohort study. Am J Kidney Dis. 2015;65:345–7.CrossRef

50.

Chang AR, Chen Y, Still C, Wood GC, Kirchner HL, Lewis M, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. Elsevier Inc; 2016;90:164–71. Available from: https://doi.org/10.1016/j.kint.2016.02.039.

51.

Reid TJ, Saeed S, McCoy S, Osewa AA, Persaud A, Ahmed L. The effect of bariatric surgery on renal function. Surg Obes Relat Dis. Elsevier; 2014;10:808–13. Available from: https://doi.org/10.1016/j.soard.2014.02.048.

52.

Li K, Zou J, Ye Z, et al. Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis. PLoS One. 2016;11:1–18.

Title: Comparative Effectiveness of Roux-en-Y Gastric Bypass vs. One Anastomosis Gastric Bypass on Kidney Function
Authors: Mohsen Mahmoudieh
Behrouz Keleidari
Pedram Hadipour
Erfan Sheikhbahaei
Alex R. Chang
Sina Ramtin
Shahab Shahabi
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Dyslipidemia
Bariatric Surgery
Bariatric Surgery
Albuminuria
Hypertension
Hypertension
Published in: Obesity Surgery / Issue 6/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-021-05295-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative Effectiveness of Roux-en-Y Gastric Bypass vs. One Anastomosis Gastric Bypass on Kidney Function

Abstract

Purpose

Materials and Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2021

Evaluating the Pharmacoeconomic Impact of Nutrient Supplementation Post-operatively on Patients Receiving Roux-Y Gastric Bypass vs. Biliopancreatic Diversion with Duodenal Switch

Analysis of National Bariatric Surgery Related Clinical Incidents: Lessons Learned and a Proposed Safety Checklist for Bariatric Surgery

Preoperative Cardiac Diagnostics in Bariatric Patients with Diabetes and Perioperative Morbidity: Results of a Cohort of 258 Patients

The Impact of Gastric Bypass on Telomere Length and Shelterin Complex Gene Expression: 6 Months Prospective Study

Impact of Bariatric Surgery on Medication Efficacy: an Analysis of World Health Organization Pharmacovigilance Data

Correction to: One Anastomosis Gastric Bypass with a Biliopancreatic Limb of 150 cm: Weight Loss, Nutritional Outcomes, Endoscopic Results, and Quality of Life at 8-Year Follow-Up